Pharmaceuticals

Durect’s Lalcostosterol Receives FDA Breakthrough Treatment Designation for Severe Alcohol-Related Hepatitis

bexib
By bexib 0 Min Read

Going forward, Durect plans to incorporate feedback from the FDA into the design of its Phase 3 trial.

You Might Also Like

Coya Therapeutics receives $5 million investment from Alzheimer’s Disease Drug Discovery Foundation

Abu Dhabi Ministry of Health Announces Partnership with Novartis and AstraZeneca

Sanyu Biopharmaceuticals unveils line of monkeypox treatments

Pharmacy Deserts and Underserved Rural Areas

UK MRC and AstraZeneca collaborate on translational clinical research

Share This Article
Previous Article Would you like to start a food truck business? What you need to know about costs (2024)
Next Article Current Markets, Land Prices, and the Importance of Trade Access, March 16, 2024 – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

China’s seapower expands as US shipyards decline
Manufacturing
Print advertising is an e-commerce opportunity
Retail & E-commerce
Top 6 banking trends to grow across Asia in 2025
Fintech
The Difference Between Direct Carrier Appointments and Producer Sub-Codes
Insurance